Cigna earnings beat by $0.04, revenue topped estimates
TÜBINGEN, GERMANY - CureVac N.V. (NASDAQ:CVAC), a biotech company currently trading near its 52-week high with an impressive 80% gain over the past six months, announced Tuesday that shareholders voted in favor of all proposals at the company’s Annual General Meeting, including key management appointments and the reappointment of its external auditor.
Axel Sven Malkomes was appointed to the Management Board, while Jean Stéphenne, Debra Barker, Craig A. Tooman, and Klaus Schollmeier were reappointed to the Supervisory Board. Mehdi Shahidi joined as a new Supervisory Board member. All appointments became effective June 24, 2025.
Shareholders also approved KPMG Accountants N.V. as the external auditor for the financial year 2026.
CureVac indicated that detailed vote tabulations will be released in the coming days, according to the company’s press release statement.
Founded in 2000, CureVac develops messenger RNA (mRNA) technology for medical applications. The company operates from its headquarters in Tübingen, Germany, with additional sites in the Netherlands, Belgium, Switzerland, and the United States.
The biotech firm focuses on developing mRNA-based therapeutics for various applications including infectious diseases and oncology, utilizing proprietary technologies designed to improve efficacy and safety while reducing costs.
In other recent news, BioNTech has announced a definitive agreement to acquire CureVac in an all-stock transaction valued at approximately $1.25 billion. This acquisition, which has received regulatory clearance from both U.S. and German authorities, is expected to strengthen BioNTech’s capabilities in mRNA-based cancer immunotherapy. CureVac’s major shareholder has agreed to tender their shares, and the deal is anticipated to close in 2025. Meanwhile, Jefferies has downgraded CureVac’s stock from buy to hold following the acquisition announcement, lowering the price target from $7.00 to $5.00. JMP Securities, however, has maintained a Market Outperform rating for CureVac, keeping a $10.00 price target due to the company’s progress in clinical developments, particularly its glioblastoma vaccine. Additionally, CureVac has received FDA clearance for a new lung cancer therapy, CVHNLC, marking a significant step in their oncology program. The company also had a favorable outcome in a patent dispute with BioNTech, as the European Patent Office upheld CureVac’s amended patent. CureVac continues to advance its mRNA technology, with clinical trials and legal proceedings ongoing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.